Acrivon Therapeutics (ACRV) Operating Leases (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Operating Leases of $1.3 million for Q1 2026, down 47.57% year-over-year from $2.4 million in Q1 2025, and down 17.83% quarter-over-quarter from $1.5 million in Q4 2025.
Acrivon Therapeutics (ACRV) Operating Leases (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Operating Leases for 6 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 47.57% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (down 47.57% YoY), while the FY2025 annual figure was $1.5 million, down 40.61% from the prior year.
- Operating Leases fell to $1.3 million in Q1 2026 per ACRV's latest filing, from $1.5 million in the prior quarter.
- Across five years, Operating Leases topped out at $4.4 million in Q3 2022 and bottomed at $1.3 million in Q1 2026.
- Historically, Operating Leases has averaged $3.0 million across 5 years, with a median of $3.2 million in 2024.
- Annual changes were most pronounced in 2023 — Operating Leases fell 11.05% — and 2026, when it sank 47.57%.
- Acrivon Therapeutics' Operating Leases stood at $4.2 million in 2022, then dropped by 11.05% to $3.8 million in 2023, then tumbled by 31.3% to $2.6 million in 2024, then tumbled by 40.61% to $1.5 million in 2025, then dropped by 17.83% to $1.3 million in 2026.
- Business Quant data shows ACRV's Operating Leases at $1.3 million in Q1 2026, $1.5 million in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Acrivon Therapeutics | 92.26 Mn | 92.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 980,000.00 |
| Mar 31, 2026 | 1.26 Mn |
| Dec 31, 2025 | 1.54 Mn |
| Sep 30, 2025 | 1.81 Mn |
| Jun 30, 2025 | 2.12 Mn |
| Mar 31, 2025 | 2.41 Mn |
| Dec 31, 2024 | 2.59 Mn |
| Sep 30, 2024 | 2.97 Mn |
| Jun 30, 2024 | 3.24 Mn |
| Mar 31, 2024 | 3.50 Mn |
| Dec 31, 2023 | 3.77 Mn |
| Sep 30, 2023 | 3.64 Mn |
| Jun 30, 2023 | 3.85 Mn |
| Mar 31, 2023 | 4.05 Mn |
| Dec 31, 2022 | 4.24 Mn |
| Sep 30, 2022 | 4.42 Mn |
| Dec 31, 2021 | 4.96 Mn |